Precision medicine could guide the development of new treatments for people living with type 2 diabetes.
Why Does Type 2 Diabetes Still Need New Drug Targets?
The World Health Organisation has set the theme for 2026 on earlier action on diabetes, bringing earlier diagnosis and better care into sharper focus. Any drug pipeline has a role in helping achieve that goal.
Type 2 diabetes affects roughly ten per cent of people worldwide.
Today’s treatments help many patients, but they leave clear areas that patients need better focus on.
First-line medicines work differently person to person and hypoglycaemia remains a risk.
Ultimately, no standard therapy reverses insulin resistance or beta-cell dysfunction, and long-term complications are difficult to manage.
Precision medicine may help by tailoring treatment to a person’s own genes, environment, and lifestyle, instead of applying one approach to everyone.
The American Diabetes Association and the European Association for the Study of Diabetes set out the position for precision medicine in diabetes in a joint 2020 consensus report.
Gut Microbiota and miRNAs Lead the New Target List
Development of new treatments for people living with type 2 diabetes now reaches into four development broader areas: Gut microbiota, epigenetic modification, GLP-1 receptor agonists, and natural killer (NK) cells.
Gut microbiota
A typical medical finding in people living with type 2 diabetes is fewer butyrate-producing bacteria, making butyrate, and bacteria such as Akkermansia muciniphila, attractive targets.
Probiotics, prebiotics, synbiotics, and postbiotics can reshape the microbiome, and an early 2022 preclinical study found that oral administration of Blautia wexlerae improved obesity and diabetes endpoints in mice.
Faecal transplants also show promise, but donor screening, processing, and long-term safety still lack standards.
miRNA therapeutics
MicroRNAs regulate metabolism across many tissues and form a relatively new class of drug targets.
In animal studies, weekly subcutaneous administration of miRNA-22-3p antagonists reduced fat mass and improved insulin sensitivity.
Additionally, antagomirs against miR-132 were found to lower blood glucose and raise insulin secretion in mice within 24 hours.
Delivery is the main hurdle. Lipid nanoparticles and chemical modifications improve stability and cell uptake but tissue specificity, immunogenicity, and long-term safety remain open challenges.
Other targets to watch
Other new targets for diabetes treatment include:
- Mitophagy: Inducers could restore mitochondrial function and insulin signalling.
- Proinsulin synthesis: Reducing proinsulin synthesis may ease beta-cell stress and support cell growth and repair.
- mTOR and FoxO1: Both metabolites shape insulin sensitivity, and tissue-specific delivery could limit side effects.
- MondoA and ChREBP: These glucose-sensing transcription factors can cause metabolic dysfunction when overloaded.
- NK cells: Vitamin D3 supplementation was found to boost NK activity in mice with type 2 diabetes.
View interview How Should Pharma Companies Audit AI Vendors?
How Should Pharma Companies Audit AI Vendors?
“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."
GLP-1 Medicines for Diabetes Treatment
Glucagon-like peptide-1 (GLP-1) receptor agonists are becoming another form of standard therapy for the treatment and management of type 2 diabetes, alongside the conventional therapies (metformin, sulfonylureas, and insulin).
Exenatide and lixisenatide act quickly to curb post-meal glucose spikes, while liraglutide, semaglutide, and dulaglutide last longer. Tirzepatide adds glucose-dependent insulinotropic polypeptide (GIP) activity to address fasting glucose.
Glucagon and GLP-1 co-agonists, as well as GLP-1 and gastrin dual agonists, glucokinase activators, and several triple agonists, now exist although the pipeline is young.
These dual mechanism molecules show how genetic subtypes can steer drug design.
As patent cliffs loom for GLPs, pushes into this space and utilising AI to do so is gaining traction.
The Challenges for Precision Diabetes Therapy
Precision therapy faces a difficult test when it comes to type 2 diabetes.
AI and machine learning may help, but there are broadly four large barriers:
- Heterogeneity: Genetic and environmental differences complicate trial and therapy design.
- Validation: Many targets have unclear clinical relevance and face long, costly development cycles.
- Equity: Algorithms need testing across diverse ethnic and geographic datasets, alongside cost-effectiveness data and generic options.
- Data: Integration, privacy, and thin primary care resources slow adoption.
These problems echo challenges in developing treatments for other diseases. Pharmatica’s Insights into target prioritisation shows how structured funnels help teams narrow long lists.
So, even while development of new treatments for people living with type 2 diabetes is expanding fast, including gut microbiota, miRNAs, mitophagy, multi-agonist peptides, and immune pathways offering new target routes, validation, delivery, and patient equity will decide which ones reach patients.
At Pharmatica, we track the drug targets, technologies, and regulatory policy shaping Pharmaceutical R&D. Explore our Insights to turn discovery science into confident strategy.
Pharmatica: Insight. Connection. Impact.
Comments (0)